28,050 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,050 shares of the company’s stock, valued at approximately $14,767,000.

A number of other hedge funds have also recently bought and sold shares of the business. Harbour Investments Inc. grew its position in shares of IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after buying an additional 16 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in IDEXX Laboratories by 1.5% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after acquiring an additional 18 shares during the last quarter. Triad Wealth Partners LLC boosted its stake in IDEXX Laboratories by 3.1% during the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock valued at $337,000 after acquiring an additional 18 shares during the last quarter. Advisory Services Network LLC grew its holdings in IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock worth $509,000 after acquiring an additional 18 shares in the last quarter. Finally, KCM Investment Advisors LLC grew its holdings in IDEXX Laboratories by 5.3% during the 4th quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock worth $255,000 after acquiring an additional 19 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup boosted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. UBS Group lifted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $554.99 on Monday. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The company has a 50-day simple moving average of $559.01 and a 200-day simple moving average of $573.33. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The firm has a market capitalization of $43.72 billion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.